Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms |
Action inhibitors |
Mechanism CREBBP inhibitors(cAMP-response element binding protein inhibitors), EP300 inhibitors(Histone acetyltransferase p300 inhibitors), EP300/CBP inhibitors(CREBBP/EP300 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC44H47F2N9O5 |
InChIKeyNORRDWRSNUOCBV-XCIZWWPASA-N |
CAS Registry2832961-58-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Preclinical | United States | 25 Mar 2024 | |
Castration-Resistant Prostatic Cancer | Preclinical | United States | 22 Mar 2024 |